Capricor Announces Plans to Pursue Clinical Program for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)

LOS ANGELES, Oct. 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB: CAPR ), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program for Duchenne Muscular Dystrophy (DMD) using CAP-1002, Capricor's lead product candidate. CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure. CAP-1002 is currently in Phase II clinical testing for adults with ischemic heart disease.

The clinical program will move forward based, in part, on data findings from the laboratory of Eduardo Marbán, M.D., Ph.D., Scientific Advisory Board Chairman of Capricor and the Director of the Cedars-Sinai Heart Institute. The data will be presented at the Late Breaking Basic Science Posters and Reception during the American Heart Association's Scientific Sessions in Chicago on November 17 th , 2014.

Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by a mutation of the dystrophin gene and is characterized by progressive muscle degeneration and weakness. Symptoms usually appear in male children before age six but may be visible in early infancy and the disorder is often fatal. Though characterized by progressive skeletal muscle weakness which often results in patients requiring the use of a wheelchair and having respiratory complications, DMD also results in cardiac dysfunction in most patients. Many deaths occur due to cardiomyopathy caused by a weakening of the cardiac muscle as a result of the gene mutation that is responsible for the disease. Many patients do not survive beyond their mid-twenties. Nearly 20,000 male children are living with the disease in the United States alone and approximately 275,000 are affected worldwide.

"We are extremely excited to develop a clinical program targeting DMD as a potential indication for our CDC platform technology," said Capricor CEO, Linda Marbán, Ph.D. "In early clinical trials, CDCs have shown to be safe and to reduce scar size in patients with ischemic heart disease. Treatment of DMD cardiomyopathy provides a unique opportunity to apply Capricor's CDC technology for the treatment of patients with a potentially fatal orphan disease. Although, there is no cure for DMD, we look forward to raising the overall scientific understanding of this disease, and hopefully to improving the lives of patients with DMD and their families."

About the Presentation

An abstract entitled, "Heart-derived Cell Therapy for Duchenne Cardiomyopathy: Cardiosphere-derived Cells and their Exosomes Improve Function, Restore Mitochondrial Integrity and Reverse Degenerative Changes in the Hearts of Mdx Mice," will be presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014. The presentation will be held between 4:00–6:00 PM on Monday, November 17th, in South Hall A2 of McCormick Place, Chicago, IL.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com .

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on August 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

For more information, please contact: Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 ProActive Capital Group Kirin Smith, COO +1-646-863-6519 www.ProActiveCapital.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 0

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 24

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

T. Rowe Price OHA Credit Fund Reports Strong Q2 Performance

Updated Category News Views 146

Financial Performance Overview T. Rowe Price OHA Select Private Credit Fund (NASDAQ: OCREDIT) recently reported its financial results for the quarter ended June 30, 2025. The fund declared total distributions amounting to $0.81 per share for this period. This reflects the growing significance of private credit as a financing solution in today's credit markets. Investment...

Continue Reading
Toll Brothers Unveils Luxurious Townhome Community in Armonk

Updated Category News Views 222

Discover the Enclave at Armonk Located in Armonk, the newly launched Enclave at Armonk invites homebuyers to experience luxury living blended with convenience. This new community by Toll Brothers represents a significant addition to the Westchester County real estate market, bringing elegant townhome designs that promise sophistication and comfort. A Closer Look at the...

Continue Reading
XAI Octagon Trust Expands Opportunities with New Preferred Shares

Updated Category News Views 108

XAI Octagon Trust Issues Convertible Preferred Shares XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT), a diversified closed-end management investment company, has made a significant move by announcing the issuance and sale of 400,000 shares of its 6.95% Series II 2029 Convertible Preferred Shares. This initiative enhances the Trust's capital resources and...

Continue Reading
Endeavour Mining's Recent Share Buyback Activity Overview

Updated Category News Views 208

Endeavour Mining Announces Recent Share Buyback In a significant move for shareholders, Endeavour Mining plc (LSE: EDV, TSX: EDV) has disclosed its recent buyback of ordinary shares. These transactions showcase the company's ongoing commitment to enhancing shareholder value and demonstrate a strategic approach to managing its equity. Details of the Share Buyback Endeavour...

Continue Reading
Sleep Awareness Week 2025: Importance of Quality Sleep

Updated Category News Views 459

National Sleep Foundation Announces 2025 Dates for Sleep Awareness Week Today, the National Sleep Foundation (NSF) has shared that Sleep Awareness Week in 2025 will be observed from March 9 to March 15. This annual campaign aims to highlight the critical role sleep plays in promoting health and overall well-being, encouraging the public to prioritize high-quality sleep....

Continue Reading